梯瓦制药(TEVA)在夜盘交易中股价大涨5.98%,引发市场广泛关注。这主要受益于公司与赛诺菲安万特合作的新药取得重大进展。
据报道,梯瓦制药与赛诺菲安万特合作开发的一种新型溃疡性结肠炎和克罗恩病新药已经达成关键的临床试验目标。这意味着新药有望顺利进入后续阶段,争取早日上市销售。专家分析,一旦成功上市,该新药有望成为全球热销药物,年销售有望超过10亿美元。
业内人士指出,此次新药临床试验取得重大进展,再加上梯瓦制药股票上周上涨34%,体现了市场对公司前景的看好。梯瓦制药业绩持续向好,研发管线丰富,有望成为生物制药板块的投资亮点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.